Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig.
Cabrian
K M
KM
Bristol-Myer Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA.
Berry
K K
KK
Shuford
W W
WW
Mittler
R S
RS
Rodgers
J N
JN
Linsley
P S
PS
D000069594:Abatacept; D000704:Analysis of Variance; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000917:Antibody Formation; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000494:pharmacology*; D060908:CTLA-4 Antigen; D006433:Hemocyanins / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates; D007074:Immunoglobulin G / Q000494:pharmacology; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008252:Macaca fascicularis; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000069594:Abatacept; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin